Hormone Replacement Therapy - Wyeth positions to strike back?

Introduction:

The early ending in 2002 of part of the US WHI study, which revealed increased risks of breast cancer and cardiovascular disease in women taking Wyeth’s Prempro, has precipitated shifts in the perception and prescribing of HRT. This is leading to a re-evaluation of R&D strategies in HRT, as companies seek to maximize returns on R&D investment in a changing and challenging market.

Scope:

* Assessment of epidemiological trends and patient potential, including disease definitions and areas of unmet need. 

* Sales data and forecasts to 2011, including evaluation of key late stage development products. 

* Transcripts of interviews with key physician and industry opinion leaders on the future of the HRT pipeline. 

* Recommendations for clinical trial design and recruitment, as well as R&D strategy for HRT companies of different sizes. 

Report Highlights:

WHI findings have precipitated the Premarin franchise sales slump. However, Prempro sales year on year actually fell for two quarters before the WHI Prempro arm was halted, suggesting problems in the Premarin franchise even before the WHI. 

The imposition of strict exclusion criteria in HRT trial recruitment is a key component of trial design. R&D managers must ensure that trial protocols exclude older women from HRT studies. 

Wyeth’s HRT pipeline is stocked with successors to the Premarin franchise. Wyeth has used licensing agreements to ensure its dominance of the HRT sector will continue beyond the Premarin franchise. 

Reasons to Purchase:

* Competitive analysis: benchmark your company against the leaders 

* R&D strategy: design trials that will maximize return on investment

* Forecasts: understand the impact of new products to 2011  

Publisher: Datamonitor Womens Health Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Womens_Health.html#a382